CVS Brings Back Coverage for Lilly's Obesity Drug Zepbound
CVS Reinstates Coverage for Zepbound
CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage.
Key Details
Caremark, CVS's pharmacy benefit management unit, had dropped Zepbound from coverage on July 1. It will return to commercial formularies on October 1, aiming to provide employers and health plans more affordable access to GLP-1 treatments.
Caremark will also remove a new-to-market block on Lilly's recently launched oral pill, Foundayo, effective June 1. This move addresses the growing demand and high costs of GLP-1 drugs.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
CVS Health Corporation
By adding Zepbound back to its formularies, CVS can attract more clients and reduce drug costs, potentially boosting profitability.
Eli Lilly and Company
Zepbound's return to CVS formularies will increase sales and expand market share for Eli Lilly.
NOVO NORDISK B A/S
Zepbound's return intensifies competition with Wegovy, potentially hurting Novo Nordisk's market share.
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…